How Durable Is Joint Replacement’s Tailwind? Chart of the Month The Numbers Our chart of the month shows combined first-quarter knee and hip replacement sales between 2019 and 2023 for the big four recon players. Jun 20, 2023
Medtronic Positioned for Spine’s Tech Turn Company Revenue The Numbers The company grew in the low single digits for its 2023 fiscal year, but its expansive technology ecosystem is a significant advantage. Jun 01, 2023
The State of Orthopedics in 2023 Videos This webinar reviews 2022 performance and drivers for orthopedic market segments and companies, as well as a look ahead to 2023. May 25, 2023
Orthopedic Executives Remain Cautious After Strong First Quarter Executive Insights Industry Voices Through 1Q23, the orthopedic market enjoyed significant growth due to improving procedure volumes, reduced headwinds and weaker comparisons. May 23, 2023
Bioventus Looks to Regain Credibility With Investors Company Revenue The Numbers The company's 1Q23 orthopedic sales declined slightly as Bioventus embarks upon a quarters-long turnaround. May 22, 2023
Anika Therapeutics Sees Traction From Recent Launches Company Revenue The Numbers The company grew its orthopedic business 9% in 1Q23, driven by favorable order timing and contributions from new products. May 16, 2023
Orthopedic Acquisitions Since 2020 Chart of the Month The Numbers Enovis has been the most acquisitive orthopedic company in recent years, with eight transactions since the beginning of 2020. May 15, 2023
Treace Medical Strengthens Position in Underserved Market Company Revenue The Numbers The company grew over 45% in 1Q23 as it further penetrates the large, underserved bunion surgical procedure market. May 15, 2023
Paragon 28 Remains Cautious Despite Hot Start to FY23 Company Revenue The Numbers The company grew 26% in 1Q23 against strong comps than most of the orthopedic industry, but opted to not increase it revenue guidance. May 15, 2023
Orthofix Completes First Quarter as Combined Company Company Revenue The Numbers The company grew 11.1% on a pro forma basis in 1Q23, driven by strength across its businesses and no major dissyngeries from the merge May 11, 2023